Optic atrophy management sales will grow through 2036, led by ethambutol at 21.7% of the drug type segment in 2026. The market was valued at USD 8.82 billion in 2025 and is expected to be worth USD 15.09 billion by 2036, creating an incremental opportunity of USD 5.82 billion.